PHARMOBEDIENT
GenericsPHARMOBEDIENT is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
PHARMOBEDIENT's Key Drugs
PHARMOBEDIENT's core commercial portfolio centers on ALLZITAL, POLMON, DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Headache
Allergic Rhinitis
Nausea and Vomiting of Pregnancy
PHARMOBEDIENT's Recent FDA Approvals
New NDA/BLA approvals for PHARMOBEDIENT over the last two years — novel drugs only, excluding generics and label supplements.
PHARMOBEDIENT's Therapeutic Areas
PHARMOBEDIENT's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMOBEDIENT's Top Competitors
PHARMOBEDIENT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMOBEDIENT Pipeline Snapshot
Active clinical trials for PHARMOBEDIENT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ALLZITAL leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (6)
Discontinued (8)
Company Info
- First Approval
- 1939-06-05
- Latest
- 2026-09-29
- Applications
- 358